射血分数保留的心力衰竭
心力衰竭
医学
射血分数
心脏病学
赛马鲁肽
内科学
炎症
肥胖
糖尿病
2型糖尿病
内分泌学
利拉鲁肽
作者
Subodh Verma,Barry A. Borlaug,Javed Butler,Melanie J. Davies,Dalane W. Kitzman,Mark C. Petrie,Sanjiv J. Shah,Nitish K Dhingra,Mikhail Kosiborod
出处
期刊:Cell Metabolism
[Elsevier]
日期:2023-10-01
卷期号:35 (10): 1681-1687
被引量:4
标识
DOI:10.1016/j.cmet.2023.08.003
摘要
In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.
科研通智能强力驱动
Strongly Powered by AbleSci AI